Abstract
In experimental sepsis (after cecal ligation and puncture, CLP) there is convincing evidence of complement activation, as there is in human sepsis. In addition, in sepsis involving rodents and humans, blood neutrophils have lost innate immune functions (chemotaxis, phagocytosis, the ability to produce H2O2). In CLP, and in neutrophils exposed to the complement anaphylatoxin, C5a, there is defective activation of MAPK (mitogen activated protein kinase), phosphorylation of p47, and inability to assemble NADPH oxidase. In experimental sepsis, the consumptive coagulopathy can be prevented by anti-C5a. Sepsis is also associated with loss of C5a receptor (C5aR) on neutrophils. In sepsis, thymocytes undergo apoptosis that is C5a mediated. All of these abnormalities occurring in experimental sepsis can be reversed by treatment with anti-C5a, with C5aR antagonist, with anti-C5aR, or with anti-IL-6, which causes upregulation of C5aR. These data suggest that generation of C5a during sepsis is harmful and that its interception or blockade of C5aR is beneficial.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Annane, D., Sebille, V., Charpentier, C., Bollaert, P.E., Francois, B., Korach, J.M., Capellier, G., Cohen, Y., Azoulay, E., Troche, G., Chaumet-Riffaut, P., Bellisant, E. Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862–871.
Bernard, G.R. Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., Fisher, C.J. Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:366–709.
Hotchkiss, R.S., Karl, I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138–150.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864–874.
Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R. Epidemiology of sever sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001; 29:1303–1310.
Ertel, W., Morrison, M.H., Wang, P., Ba, Z.F., Ayala, A., Chaudry, I.H. The complex pattern of cytokines in sepsis. Ann Surg 1991; 214:141–148.
Beutler, G., Milsark, I.W., Cerami, A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229: 869–871.
Abraham, E., Wunderink, R., Silverman, H., Perl, T.M., Nasraway, S., Levy, H., Bone, R., Wenzel, R.P., Balk, R., Allred, R., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273:934–41.
Mohr, M., Hopken, U., Oppermann, M., Mathes, C., Goldmann, K., Siever, S., Gotze, O., Burchardi, H. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 1998; 28(3):227–234.
Stevens, J.H., O’Hanley, P., Shapiro, J.M., Mihm, F.G., Satoh, P.S., Collins, J.A., Raffin, T.A. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 6:1812–1816.
Hangen, D.H., Stevens, J.H., Satoh, P.S., Hall, E.W., O’Hanley, P.T., Raffin, T.A. Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 1989;46(3):195–199.
Deitch, E.A. Animal models of sepsis and shock: a review and lessons learned. Shock 1997;9:1–11.
Wichterman, K.A., Baue, A.E., Chaudry, I.H. Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 1980; 29:189–201.
Huber-Lang, M., Sarma, V.J., Lu, K.T., McGuire, S.R., Padgaonkar, V.A., Guo, R.F., Younkin, E.M., Kunkel, R.G., Ding, J., Erickson, R., Curnutte, J.T., Ward, P.A. Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 166:1193–1199.
Czermak, B.J., Breckwoldt, M., Ravage, Z.B., Huber-Lang, M., Schmal, H., Bless, N.M., Friedl, H.P., Ward, P.A. Mechanism of enhanced lung injury during sepsis. Am J Pathol 1999; 154:1057–1065.
Nakae, H., Endo, S., Inada, K., Yoshida, M. Chronological changes in the complement system in sepsis. Surg Today 1996; 26:225–229.
Bengtson, A., Heideman, M. Anaphylatoxin formation of sepsis. Arch Surg 1988; 123(5):645–649.
Furebring, M., Hakansson, L.D., Venge, P., Nilsson, B., Sjolin, J. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 2002; 6:363–370.
Huber-Lang, M., Younkin, E.M., Sarma, V.J., McGuire, S.R., Lu, K.T., Guo, R.F., Padgaonkar, V.A., Curnutte, J.T., Erickson, R., Ward, P.A. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002; 169:3223–3231.
Bone, R.C., Grodzin, C.J., Balk, R.A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235–243.
Matsukawa, A., Hogaboam, C.M., Lukacs, N.W., Lincoln, P.M., Strieter, R.M., Kunkel, S.L. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 1999; 163:6148–6154.
Qiu, G., Wang, C., Smith, R., Harrison, K., Yin, K. Role of IFN-gamma in bacterial containment in a model of intra-abdominal sepsis. Shock 2001; 16:425–429.
Matsukawa, A., Hogaboam, C.M., Lukacs, N.W., Lincoln, P.M., Evanoff, H.L., Strieter, R.M., Kunkel, S.L. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000; 164:2738–2744.
Ayala, A., Deol, Z.K., Lehman, D.L., Herdon, C.D., Chaudry, I.H. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 1994; 56:579–585.
Hamilton, T.A., Ohmori, Y., Tebo, J. Regulation of chemokine expression by antiinflammatory cytokines. Immunol Res 2002; 25:229–245.
Huber-Lang, M., Sarma, V.J., McGuire, S.R., Lu, K.T., Guo, R.F., Padgaonkar, V.A., Younkin, E.M., Laudes, I.J., Riedemann, N.C., Younger, J.G., Ward, P.A. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15:568–570.
McCabe, W.R. Serum complement levels in bacteremia due to gram negative organisms. N Engl J Med 1973; 288:21–23.
Hecke, F., Schmidt, U., Kola, A., Bautsch, W., Klos, A., Kohl, J. Circulating complement proteins in multiple trauma patients-correlation with injury severity, development of sepsis, and outcome. Crit Care Med 1997; 12:2015–2024.
Riedemann, N.C., Guo, R.F., Neff, T.A., Laudes, I.J., Keller, K.A., Sarma, V.J., Markiewski, M.M., Mastellos, D., Strey, C.W., Pierson, C.L., Lambris, J.D., Zetoune, F.S., Ward, P.A. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110:101–108.
Riedemann, N.C., Neff, T.A., Guo, R.F., Bernacki, K.D., Laudes, I.J., Sarma, J.V., Lambris, J.D., Ward, P.A. Protective effects of IL-6 blockade in sepsis are linked to reduced c5a receptor expression. J Immunol 2003; 170:503–507.
Schieferdecker, H.L., Schlaf, G., Koleva, M., Gotze, O., Jungermann, K. Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J Immunol 2000; 164:5453–5458.
Laudes, I.J., Chu, J.C., Huber-Lang, M., Gou, R.F., Riedemann, N.C., Sarma, J.V., Mahdi, F., Murphy, H.S., Speyer, C., Lu, K.T., Lambris, J.D., Zetoune, F.S., Ward, P.A. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol, 2002; 169:5962–5970.
Laudes, I.J., Chur, J.C., Sikranth, S., Huber-Lang, M., Guo, R.F., Riedemann, N., Sarma, J.V., Schmair, A.H., Ward, P.A. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160:1867–1875.
Ikeda, K., Nagasawa, K., Horiuchi, T., Nishizaka, H., Niho, Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77:394–398.
Foreman, K.E., Vaporciyan, A.A., Bonish, B.K., Jones, M.L., Johnson, K.J., Glovsky, M.M., Eddy, S.M., Ward, P.A. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147–1155.
Hiramatsu, M., Hotchkiss, R.S., Karl, I.E., Buchman, T.G. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. Shock 1997; 7:247–253.
Ayala, A., Herdon, C.D., Lehman, D.L., Ayala, C.A., Chaudry, I.H. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 1996; 87:4261–4275.
Hotchkiss, R.S., Swanson, P.E., Cobb, J.P., Jacobson, A., Buchman, T.G., Karl, I.E. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T-and B-cell-deficient mice. Crit Care Med 1997; 25:1298–1307.
Coopersmith, C.M., Chang, K.C., Swanson, P.E., Tinsley, K.W., Stromberg, P.E., Buchman, T.G., Karl, I.E., Hotchkiss, R.S. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med 2002; 30:195–201.
Hotchkiss, R.S., Chang, K.C., Swanson, P.E., Tinsley, K.W., Hui, J.J., Klender, P., Xanthoudakis, S., Roy, S., Black, C., Grimm, E., Aspiotis, R., Han, Y., Nicholson, D.W., Karl, I.E. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1(6):496–501.
Guo, R.F., Huber-Lang, M., Wang, X., Sarma, V., Padgaonkar, V.A., Craig, R.A., Riedemann, N.C., McClintock, S.D., Hlaing, T., Shi, M.M., Ward, P.A. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000; 106:1271–1280.
Riedemann, N.C., Guo, R.F., Laudes, I.J., Keller, K., Sarma, V.J., Padgaonkar, V., Zetoune, F.S., Ward, P.A. C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002; 16:887–888.
Czermak, B.J., Sarma, V., Pierson, C.L., Warner, R.L., Huber-Lang, M., Bless, N.M., Schmal, H., Friedl, H.P., Ward, P.A. Protective effects of C5a blockade in sepsis. Nature Med 1999; 5:788–792.
Strachan, A.J., Woodruff, T.M., Haaima, G., Fairlie, D.P., Taylor, S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol 2000; 164:6560–6565.
Huber-Lang, M., Riedemann, N.C., Sarma, V.J., Younkin, E.M., McGuire, S.R., Laudes, I.J., Lu, K.T., Guo, R.F., Neff, T.A., Padgaonkar, V.A., Lambris, J., Spruce, L., Mastellos, D., Zetoune, F.S., Ward, P.A. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16:1567–1574.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Zetoune, F.S., Ward, P.A., Huber-Lang, M.S. (2004). Role of C5a and C5a Receptor in Sepsis. In: Szebeni, J. (eds) The Complement System. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8056-5_21
Download citation
DOI: https://doi.org/10.1007/1-4020-8056-5_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-8055-5
Online ISBN: 978-1-4020-8056-2
eBook Packages: Springer Book Archive